The Fall of Pfizer: How Big is Too Big for Pharma Innovation?

Quote




Anonymous said:
http://www.xconomy.com/national/201...zer-how-big-is-too-big-for-pharma-innovation/
Click to expand...

"...What the excellent and groundbreaking Pfizer article makes clear is that the arrogant and ignorant mismanagement of the motivations and rewards of the top leadership was at the core of Pfizer’s decline. It wasn’t about the failure of thousands but the failure of a few. Once low emotional intelligence takes hold in the executive suite, value destruction follows. Too often shareholders and advisors ignore or deprioritize the kind of values-based culture in which innovation thrives. They over-control and over-measure and reward the wrong behaviors in favor of short-term objectives. This is the cause of innovation decline, not bigness."
 




Pfizer is the Blackberry of computing watching biotech Apples pass it by in shareholder value.

The fact that this salesforce is using dinosaur laptops and got "new" Blackberry's speaks volumes in itself that the current structure does not lend itself to a culture of innovation in its stodgy, monolithic DNA of old "Pfizer".
 
































Top Bottom
Back
Quote